Insider Trading Alert - MPWR, SKUL And AMAG Traded By Insiders

Stocks with insider trader activity include MPWR, SKUL and AMAG
By TheStreet Wire ,

Yesterday, Nov. 10, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $354.40 to $12,639,826.44.

Highlighted Stocks Traded by Insiders:

Monolithic Power Systems (MPWR) - FREE Research Report

Rao Meera, who is Cfo at Monolithic Power Systems, sold 3,754 shares at $63.91 on Nov. 10, 2015. Following this transaction, the Cfo owned 179,592 shares meaning that the stake was reduced by 2.05% with the 3,754-share transaction.

The shares most recently traded at $63.81, down $0.10, or 0.15% since the insider transaction. Historical insider transactions for Monolithic Power Systems go as follows:

  • 4-Week # shares sold: 30,632
  • 12-Week # shares sold: 44,452
  • 24-Week # shares sold: 83,925

The average volume for Monolithic Power Systems has been 308,600 shares per day over the past 30 days. Monolithic Power Systems has a market cap of $2.5 billion and is part of the technology sector and electronics industry. Shares are up 27.88% year-to-date as of the close of trading on Tuesday.

Monolithic Power Systems, Inc. designs, develops, and markets integrated power semiconductor solutions and power delivery architectures for communications, storage and computing, consumer electronics, and industrial/automotive markets. The stock currently has a dividend yield of 1.25%. The company has a P/E ratio of 76.2. Currently, there are 7 analysts who rate Monolithic Power Systems a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MPWR - FREE

TheStreet Quant Ratings

rates Monolithic Power Systems as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Monolithic Power Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skullcandy (SKUL) - FREE Research Report

Alden Rick, who is Director at Skullcandy, sold 25,000 shares at $4.62 on Nov. 10, 2015. Following this transaction, the Director owned 883,597 shares meaning that the stake was reduced by 2.75% with the 25,000-share transaction.

The shares most recently traded at $4.50, down $0.12, or 2.67% since the insider transaction. Historical insider transactions for Skullcandy go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 150,000
  • 12-Week # shares bought: 17,000
  • 12-Week # shares sold: 387,500
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 387,500

The average volume for Skullcandy has been 192,500 shares per day over the past 30 days. Skullcandy has a market cap of $136.8 million and is part of the consumer goods sector and consumer durables industry. Shares are down 50.82% year-to-date as of the close of trading on Tuesday.

Skullcandy Inc. designs, markets, and distributes audio and gaming headphones, earbuds, speakers, and other accessories under the Skullcandy, Astro Gaming, and 2XL brands in the United States and internationally. The company has a P/E ratio of 19.2. Currently, there are 4 analysts who rate Skullcandy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKUL - FREE

TheStreet Quant Ratings

rates Skullcandy as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and weak operating cash flow. Get the full

Skullcandy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AMAG Pharmaceuticals (AMAG) - FREE Research Report

Fallon John A., who is Director at AMAG Pharmaceuticals, bought 3,230 shares at $31.20 on Nov. 10, 2015. Following this transaction, the Director owned 6,086 shares meaning that the stake was boosted by 113.1% with the 3,230-share transaction.

The shares most recently traded at $29.49, down $1.71, or 5.8% since the insider transaction. Historical insider transactions for AMAG Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 64,125

The average volume for AMAG Pharmaceuticals has been 1.4 million shares per day over the past 30 days. AMAG Pharmaceuticals has a market cap of $959.6 million and is part of the health care sector and drugs industry. Shares are down 31.16% year-to-date as of the close of trading on Tuesday.

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. The company has a P/E ratio of 4.8. Currently, there are 5 analysts who rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMAG - FREE

TheStreet Quant Ratings

rates AMAG Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and a generally disappointing performance in the stock itself. Get the full

AMAG Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...